Tanvex BioPharma (TPE:6541) Total Long-Term Assets: NT$6,464.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6541 Tanvex BioPharma Inc TPE:6541
43 GF Score
Price NT$36.60
! 4 Warning Signs
View Full Analysis

What is Tanvex BioPharma Total Long-Term Assets?

Tanvex BioPharma TPE:6541 -3.17% 43 Total Long-Term Assets is NT$6,464.0 Mil as of Dec. 2025. GuruFocus rates TPE:6541 with a GF Score™ of 43/100. The stock has 4 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Tanvex BioPharma's Total Long-Term Assets for the quarter that ended in Dec. 2025 was NT$6,464.0 Mil.

Tanvex BioPharma Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Tanvex BioPharma's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tanvex BioPharma Total Long-Term Assets Chart

Tanvex BioPharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,311.60 2,376.10 2,159.19 2,059.51 6,463.95

Tanvex BioPharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,059.51 6,153.97 5,714.07 6,113.55 6,463.95
TPE:6541
43GF Score
Tanvex BioPharma Inc TPE:6541
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tanvex BioPharma Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of NT$6,464.0 Mil mean?
Tanvex BioPharma (TPE:6541) has a Total Long-Term Assets of NT$6,464.0 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Tanvex BioPharma and its competitors.
Is Tanvex BioPharma's Total Long-Term Assets too high?
Tanvex BioPharma's current Total Long-Term Assets is NT$6,464.0 Mil. Overall, Tanvex BioPharma has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's Total Long-Term Assets compare to VRTX and REGN?
Tanvex BioPharma's Total Long-Term Assets of NT$6,464.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Tanvex BioPharma and its competitors. Tanvex BioPharma's current Total Long-Term Assets is NT$6,464.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Tanvex BioPharma (TPE:6541) has a current Total Long-Term Assets of NT$6,464.0 Mil. The current Total Long-Term Assets is NT$6,464.0 Mil. Tanvex BioPharma's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current Total Long-Term Assets is NT$6,464.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tanvex BioPharma Business Description

Address No. 12-2, Shengyi Road, Section 2, 6th Floor, Hsinchu County, Zhubei, TWN, 106
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
43GF Score

Get the complete analysis for TPE:6541

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$36.60
Price